Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.

Clinical Nuclear Medicine
Pierre SesquesEmmanuel Bachy

Abstract

We aimed to evaluate the role of 18F-FDG PET/CT in predicting patient outcome following chimeric antigen receptor T (CAR T) cells infusion in aggressive B-cell lymphoma. 18F-FDG PET/CT data before leukapheresis, before CAR T-cell infusion and 1 month (M1) after CAR T-cell infusion, from 72 patients were retrospectively analyzed. SUVmax, total lesion glycolysis (TLG), metabolic tumor volume (MTV), and parameters describing tumor kinetics were calculated for each 18F-FDG PET/CT performed. The aim was to evaluate the prognostic value of 18F-FDG PET/CT metabolic parameters for predicting progression-free survival (PFS) and overall survival (OS) following CAR T-cell therapy. Regarding PFS, ∆MTVpre-CAR and ∆TLGpre-CAR were found to be more discriminating compared with metabolic parameters at preinfusion. Median PFS in patients with a ∆MTVpre-CAR of less than 300% was 6.8 months (95% confidence interval [CI], 2.8 months to not reached) compared with 2.8 months (95% CI, 0.9-3.0 months) for those with a value of 300% or greater (P = 0.004). Likewise, median PFS in patients with ∆TLGpre-CAR of less than 420% was 6.8 months (95% CI, 2.8 months to not reached) compared with 2.7 months (95% CI, 1.3-3.0 months) for those with a value of 420%...Continue Reading

References

Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malik E JuweidUNKNOWN Imaging Subcommittee of International Harmonization Project in Lymphoma
Sep 18, 2007·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Chieh LinMichel Meignan
Apr 22, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Martin Hutchings, Sally F Barrington
Feb 27, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Michel MeignanAnnibale Versari
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Dec 3, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Ronald BoellaardUNKNOWN European Association of Nuclear Medicine (EANM)
Feb 24, 2016·European Journal of Nuclear Medicine and Molecular Imaging·N George MikhaeelSally F Barrington
Mar 5, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne-Ségolène CottereauStéphanie Becker
Oct 19, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Anne-Ségolène CottereauStéphanie Becker
Dec 3, 2017·Seminars in Nuclear Medicine·Lale Kostakoglu, Stéphane Chauvie
Dec 12, 2017·The New England Journal of Medicine·Sattva S NeelapuWilliam Y Go
Dec 7, 2018·The New England Journal of Medicine·Stephen J SchusterUNKNOWN JULIET Investigators
Feb 16, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jiasheng WangKui Zhao
May 14, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Loretta J NastoupilFrederick L Locke
Jul 16, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Caron A JacobsonUtkarsh H Acharya

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.